Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
- PDF / 956,568 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 69 Downloads / 213 Views
ORIGINAL RESEARCH
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data Joseph A. Lasky
. Gerard J. Criner . Howard M. Lazarus .
Veronika Kohlbrenner . Shaun Bender . Luca Richeldi
Received: May 29, 2020 Ó The Author(s) 2020
ABSTRACT Introduction: The safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) have been characterized using data from clinical trials. Methods: We further characterized the safety and tolerability of nintedanib in patients with IPF in clinical practice using the global pharmacovigilance database. The database included spontaneously reported adverse events and data collected via solicited reporting in patients treated with nintedanib from 15 October 2014 Joseph A. Lasky and Gerard J. Criner contributed equally to this article.
Digital Features To view digital features for this article go to https://doi.org/10.6084/m9.figshare.12666482. J. A. Lasky (&) School of Medicine, Tulane University, New Orleans, LA, USA e-mail: [email protected] G. J. Criner Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA H. M. Lazarus V. Kohlbrenner S. Bender Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA L. Richeldi Fondazione Policlinico A. Gemelli IRCCS, Universita` Cattolica del Sacro Cuore, Rome, Italy
to 15 October 2018. Adverse events were coded using the Medical Dictionary for Regulatory Activities. Cumulative exposure to nintedanib was estimated on the basis of sales data. Results: Cumulative exposure to nintedanib was estimated as 60,107 patient-years. Diarrhea was the most frequent event (301.6 events per 1000 patient-years). Most (97.0%) diarrhea events were non-serious. The median (25th, 75th percentile) time to onset of the first diarrhea event was 60 (11, 182) days. Elevated liver enzyme or bilirubin levels were reported at a rate of 31.5 events per 1000 patient-years. Bleeding was reported at a rate of 36.8 events per 1000 patient-years; 81.0% of events were non-serious. Major cardiovascular adverse events were reported at a rate of 13.4 events per 1000 patient-years and myocardial infarction at a rate of 4.3 events per 1000 patient-years. Gastrointestinal perforation was reported at a rate of 1.0 event per 1000 patient-years. Conclusions: On the basis of pharmacovigilance data collected over 4 years, the safety profile of nintedanib in patients with IPF was consistent with that observed in clinical trials and described in the product label, with no new safety concerns observed.
Adv Ther
Graphical Abstract:
Keywords: Interstitial lung diseases; Monitoring; Drug; Postmarketing drug surveillance; Tyrosine kinase inhibitor Key Summary Points Why carry out this study? We used data from Boehringer Ingelheim’s global pharmacovigilance program to study the safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis (IPF), based on a larger and broader patient population and a longer follow-up period than
Data Loading...
